Therapeutic drug monitoring guided fluconazole therapy in a patient with cholangitis sepsis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109347" target="_blank" >RIV/00843989:_____/22:E0109347 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/22:A2302JC3

Výsledek na webu

<a href="https://www.futuremedicine.com/doi/epub/10.2217/pme-2021-0010" target="_blank" >https://www.futuremedicine.com/doi/epub/10.2217/pme-2021-0010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/pme-2021-0010" target="_blank" >10.2217/pme-2021-0010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Therapeutic drug monitoring guided fluconazole therapy in a patient with cholangitis sepsis

Popis výsledku v původním jazyce

Candida and other fungal species play an increasing role in nosocomial infections, including cholangitis and cholangiosepsis. Early diagnosis and prompt treatment are essential in successful patient outcomes. Fluconazole is an antifungal of choice in fluconazole-sensitive Candida infections. Little information is known about the fluconazole biliary excretion. Decreased tissue penetration may be one of the possible causes of treatment failure. Due to favorable pharmacokinetics, therapeutic drug monitoring of this antifungal has not been recommended routinely. In the presented case we report the successful therapeutic drug monitoring-guided fluconazole treatment in a patient with cholangitis and cholangiosepsis caused by fluconazole-sensitive Candida spp.

Název v anglickém jazyce

Therapeutic drug monitoring guided fluconazole therapy in a patient with cholangitis sepsis

Popis výsledku anglicky

Candida and other fungal species play an increasing role in nosocomial infections, including cholangitis and cholangiosepsis. Early diagnosis and prompt treatment are essential in successful patient outcomes. Fluconazole is an antifungal of choice in fluconazole-sensitive Candida infections. Little information is known about the fluconazole biliary excretion. Decreased tissue penetration may be one of the possible causes of treatment failure. Due to favorable pharmacokinetics, therapeutic drug monitoring of this antifungal has not been recommended routinely. In the presented case we report the successful therapeutic drug monitoring-guided fluconazole treatment in a patient with cholangitis and cholangiosepsis caused by fluconazole-sensitive Candida spp.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Personalized medicine

ISSN

1741-0541

e-ISSN

1744-828X

Svazek periodika

19

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

9-14

Kód UT WoS článku

000715367700001

EID výsledku v databázi Scopus

2-s2.0-85122128628